Irritable Bowel Syndrome in US 2026 depend on the diagnostic criteria used: the widely quoted figure of about 12% of adults comes from older Rome III-era surveys, while a 2023 nationwide survey of 88,607 Americans found 6.1% met the stricter Rome IV criteria. Women are affected about twice as often as men (6.1% versus 3.2% under Rome IV), subtype shares are close to one-third each for mixed (33.9%), constipation-predominant (33.6%) and diarrhea-predominant (28.1%) IBS, and direct medical costs run $1.5 billion to $10 billion a year.
Irritable Bowel Syndrome in US 2026 – Introduction
Irritable Bowel Syndrome in US 2026 need a definition before any number. IBS is a disorder of gut-brain interaction marked by recurrent abdominal pain linked to bowel habit changes. No blood test or scan confirms it, so doctors diagnose it from symptoms using the Rome criteria. Rome III counted people with milder or less frequent pain, and Rome IV, published in 2016, requires pain at least once a week. The stricter rule roughly halves the prevalence.
This report combines three kinds of sources: US population surveys using Rome III and Rome IV, global meta-analyses published in 2025, and cost studies, including a 2026 systematic review and the American College of Gastroenterology’s 2026 patient infographic. The tables name each source, year and criteria, since the 12% headline, the 6.1% survey result and the 17% global Rome IV meta-analysis all measure different things. This report is for information and does not replace medical advice.
Interesting Facts About Irritable Bowel Syndrome in US 2026
IBS PREVALENCE BY SOURCE AND CRITERIA (% OF ADULTS)
Global, Rome IV (2025 meta-analysis) ████████████████████████████████████████ 17.1
Global, Rome III (2025 meta-analysis) ██████████████████████████████░░░░░░░░░░ 13.2
Commonly cited worldwide figure ████████████████████████████░░░░░░░░░░░░ 12.0
US, Rome III (3-country survey) ████████████████████░░░░░░░░░░░░░░░░░░░░ 8.8
US, Rome IV (88,607-person survey) ██████████████░░░░░░░░░░░░░░░░░░░░░░░░░░ 6.1
US, Rome IV (3-country survey) ███████████░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ 4.8
| Metric | Latest Data Point |
|---|---|
| US prevalence, Rome IV (nationwide survey, 88,607 people) | 6.1% |
| US prevalence, Rome IV (earlier estimates) | 4.7%–5.3% |
| US prevalence, Rome III (3-country survey) | 8.8% |
| Commonly cited worldwide prevalence | About 12% |
| Women vs men, Rome IV (US, Canada, UK) | 6.1% vs 3.2% |
| Women vs men, Rome III (US, Canada, UK) | 12.2% vs 5.8% |
| IBS-M / IBS-C / IBS-D / IBS-U (US, Rome IV) | 33.9% / 33.6% / 28.1% / 4.4% |
| Direct medical costs of IBS in the US (ACG 2026) | $1.5 billion to $10 billion a year |
| Total direct and indirect costs (IFFGD, cited) | Over $20 billion a year |
| Physician visits for IBS (IFFGD, cited) | Over 3.1 million a year |
| Range of annual direct cost per US patient (2026 review) | $1,661 to $31,113 |
Data source: Gastroenterology (2023–2024), Prevalence and Burden of Illness of Rome IV IBS; Gastroenterology (2020), Prevalence of Rome IV Functional Bowel Disorders in the US, Canada and UK; Cureus (2025) and Gastroenterology & Hepatology monographs; American College of Gastroenterology IBS infographic (2026); Journal of Gastroenterology and Hepatology (2026), Cost-of-Illness of IBS.
The “12% of Americans have IBS” figure is real but dated. The American College of Gastroenterology’s patient materials and many reviews cite a global prevalence near 12%, based largely on surveys that used Rome II and Rome III criteria. A nationwide US survey of 88,607 people using Rome IV found 6.1%, slightly higher than the earlier Rome IV estimates of 4.7%–5.3%. In a three-country sample, the US prevalence was 8.8% by Rome III and 4.8% by Rome IV.
The rows on subtypes and costs show a heterogeneous condition. Mixed and constipation-predominant IBS each affected about one-third of US cases, and diarrhea-predominant IBS affected 28.1%. The ACG puts direct costs at $1.5 billion to $10 billion, a wide range that reflects different methods. Irritable Bowel Syndrome Statistics in US 2026 therefore describe a common condition whose measured size depends on the question asked.
IBS Prevalence in the US 2026: How Rome III and Rome IV Change the Count
US IBS PREVALENCE BY STUDY AND CRITERIA (%)
Rome III, women (US/CA/UK) ████████████████████████████████████████ 12.2
Rome III, US only (3-country) █████████████████████████████░░░░░░░░░░░ 8.8
Rome IV, US nationwide (2023) ████████████████████░░░░░░░░░░░░░░░░░░░░ 6.1
Rome IV, women (US/CA/UK) ████████████████████░░░░░░░░░░░░░░░░░░░░ 6.1
Rome IV, US (3-country) ████████████████░░░░░░░░░░░░░░░░░░░░░░░░ 4.8
Rome IV, men (US/CA/UK) ██████████░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ 3.2
| Study | Criteria | Sample | US Prevalence |
|---|---|---|---|
| Lacy et al., nationwide survey | Rome IV | 88,607 US adults | 6.1% |
| Earlier US estimates | Rome IV | Smaller samples | 4.7%–5.3% |
| Palsson et al. (2020), US portion | Rome IV | 1,949 US adults | 4.8% |
| Palsson et al. (2020), US portion | Rome III | 1,949 US adults | 8.8% |
| Palsson et al. (2020), all three countries | Rome IV / Rome III | 5,931 adults | 4.6% / 9.2% |
| Global meta-analysis (2025) | Rome III / Rome IV | 188,885 people, 43 studies | 13.21% / 17.14% |
| Review citing worldwide prevalence | Mixed | Not applicable | About 12% |
Data source: Lacy et al., Gastroenterology (2023–2024); Palsson et al., Gastroenterology (2020); Global Prevalence of Irritable Bowel Syndrome: An Updated Systematic Review and Meta-Analysis (2025); Rome criteria monograph (PMC).
The same population produces two different rates. In the US sample of 1,949 adults, Rome III found 8.8% and Rome IV found 4.8%, a drop of about 45% (report calculation). The researchers attribute the gap to the higher minimum pain frequency in Rome IV. Rome IV requires abdominal pain on average at least one day a week, while Rome III counted less frequent pain.
The 2023 nationwide survey of 88,607 people adds a larger sample, at 6.1%. Global meta-analyses reach higher numbers because they pool online surveys and heterogeneous studies: 13.21% under Rome III and 17.14% under Rome IV in the 2025 analysis. Applying 6.1% to US adults gives about 61 per 1,000 adults, and 12% would give 120 (report calculation). Because Irritable Bowel Syndrome Statistics in US 2026 vary this much, citations should always name the criteria.
IBS by Gender and Age in the US 2026: Women, Men and Younger Adults
IBS PREVALENCE BY SEX (%)
Rome III women ████████████████████████████████████████ 12.2
Rome III men ██████████████████░░░░░░░░░░░░░░░░░░░░░░ 5.8
Rome IV women ████████████████████░░░░░░░░░░░░░░░░░░░░ 6.1
Rome IV men ██████████░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ 3.2
| Group | Rome IV Prevalence | Rome III Prevalence |
|---|---|---|
| Women (US, Canada, UK) | 6.1% | 12.2% |
| Men (US, Canada, UK) | 3.2% | 5.8% |
| Women-to-men ratio | 1.9 | 2.1 |
| Global women, 2025 meta-analysis | 20.17% | 15.69% |
| Global men, 2025 meta-analysis (Rome III) | Not stated here | 11.10% |
| Women-to-men ratio, global, Rome III | Not applicable | 1.41 |
| Factors with higher odds of IBS (US survey) | Younger adults and women | Not applicable |
Data source: Palsson et al., Gastroenterology (2020), Table 2 (combined US, Canada and UK sample); Lacy et al., Gastroenterology (2023–2024); Global Prevalence of Irritable Bowel Syndrome meta-analysis (2025). Ratios are report calculations.
Women have IBS roughly twice as often as men. In the three-country sample, Rome IV prevalence was 6.1% in women and 3.2% in men, a ratio of 1.9, and the Rome III ratio was 2.1 (report calculations). The 2025 global meta-analysis found a smaller but consistent gap, 15.69% in women against 11.10% in men under Rome III, a ratio of 1.41. The difference was significant in every analysis.
Age also matters. The 2023 US nationwide survey found that younger adults and women had higher odds of meeting Rome IV criteria. Other risk factors reported in the literature include infectious gastroenteritis: post-infectious IBS accounts for from 7% to more than one-third of cases in pooled studies. A sex gap of this size is a reliable part of Irritable Bowel Syndrome Statistics in US 2026, though researchers cannot say how much is biology and how much is care seeking.
IBS Types and Subtypes in the US 2026: IBS-C, IBS-D, IBS-M and IBS-U
IBS SUBTYPE SHARES, US ROME IV SURVEY (% OF IBS CASES)
IBS-M (mixed) ██████████████████████████████████████░░ 33.9
IBS-C (constipation) █████████████████████████████████████░░░ 33.6
IBS-D (diarrhea) ████████████████████████████████░░░░░░░░ 28.1
IBS-U (unclassified) █████░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ 4.4
| Subtype | US Nationwide Survey (Rome IV) | US, Canada, UK Survey (Rome IV) | Global Meta-Analysis |
|---|---|---|---|
| IBS-M (mixed) | 33.9% (1,838) | 31.0% | 31.4% |
| IBS-C (constipation-predominant) | 33.6% (1,819) | 28.5% | 26.1% |
| IBS-D (diarrhea-predominant) | 28.1% (1,521) | 35.0% | 26.5% |
| IBS-U (unclassified) | 4.4% (236) | 5.5% | 8.3% |
| IBS-D under Rome III (global) | Not applicable | Not applicable | 26.2% |
| IBS-C under Rome IV (global) | Not applicable | Not applicable | 34.2% |
Data source: Lacy et al., Gastroenterology (2023–2024); Lacy et al., Neurogastroenterology & Motility (2024), citing the three-country survey; global prevalence and risk factors meta-analysis, 96 studies from 52 countries (2025).
Mixed IBS is the largest US subtype at 33.9%, closely followed by IBS-C at 33.6% and IBS-D at 28.1%. Only 4.4% could not be classified. The numbers are from 5,414 people who met Rome IV criteria in the nationwide survey, which reported counts of 1,838, 1,819, 1,521 and 236 for the four subtypes. Those counts sum to 5,414 (report calculation).
Surveys do not agree on the largest subtype. The three-country sample put IBS-D first at 35.0%, while the nationwide US survey put it third at 28.1%. The global meta-analysis found IBS-M most common, at 31.4%, and IBS-C more common under Rome IV (34.2%) than under Rome III. Subtype affects treatment, because laxative-type drugs and anti-diarrheal drugs differ. For Irritable Bowel Syndrome Statistics in US 2026, the safe summary is that the three main types are roughly equal in size.
IBS Symptoms and Diagnosis in the US 2026: Rome IV Criteria and Red Flags
ROME IV CRITERIA, KEY THRESHOLDS
Pain frequency (days per week, minimum) ████░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ 1
Months with symptoms before diagnosis ████████████████████████░░░░░░░░░░░░░░░░ 6
Months of active symptoms (last) ████████████░░░░░░░░░░░░░░░░░░░░░░░░░░░░ 3
Required linked symptoms (at least) ████████░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ 2
| Diagnostic Element | Rome IV Requirement or Finding |
|---|---|
| Core symptom | Recurrent abdominal pain on average at least 1 day per week in the last 3 months |
| Linked features (at least 2) | Related to defecation; change in stool frequency; change in stool form |
| Symptom onset | At least 6 months before diagnosis |
| Subtype basis | Predominant stool form (Bristol scale) on days with abnormal bowel habits |
| Common additional symptoms | Bloating, distension, sensation of incomplete evacuation, mucus in stool |
| Red flags prompting testing | Anemia, rectal bleeding, unintentional weight loss, family history of colorectal cancer or inflammatory bowel disease |
| Post-infectious IBS share of cases | 7% to over one-third |
| Biomarker test for IBS | None; diagnosis is symptom-based |
Data source: Rome criteria and a Diagnostic Approach to IBS (Gastroenterology & Hepatology monograph, PMC); Rome Foundation Rome IV criteria; Factors related to IBS in the UK Biobank (2022) for post-infectious IBS.
The Rome IV rule explains the prevalence change. A person must have abdominal pain on average at least 1 day a week over the last 3 months, plus 2 or more of three features: pain related to defecation, a change in how often stools occur, or a change in stool form. Symptoms must have started at least 6 months before diagnosis. Under Rome III, pain needed to occur only 3 days a month, so more people qualified.
Doctors diagnose IBS by symptoms and by ruling out other disease. Red flags such as anemia, bleeding, unintended weight loss or a family history of colorectal cancer or inflammatory bowel disease require further testing, because they are not part of IBS. Bloating and a feeling of incomplete evacuation are common. A symptom-based test means that two doctors applying different criteria can reach different counts, which is why Irritable Bowel Syndrome Statistics in US 2026 carry wide ranges.
IBS Costs and Healthcare Burden in the US 2026
IBS COST ESTIMATES (BILLIONS USD PER YEAR)
Direct costs, upper bound (ACG) ████████████████████░░░░░░░░░░░░░░░░░░░░ 10
Direct costs, lower bound (ACG) ███░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ 1.5
Total direct + indirect (IFFGD) ████████████████████████████████████████ 20+
| Cost or Utilization Measure | Value |
|---|---|
| Direct medical costs, US | $1.5 billion to $10 billion a year (ACG, 2026) |
| Total direct and indirect costs, US | Over $20 billion a year (IFFGD, as cited) |
| Physician visits for IBS, US | Over 3.1 million a year (IFFGD, as cited) |
| Annual direct cost per US patient, range of studies | $1,661 to $31,113 (IBS-C) |
| Incremental annual cost over matched controls (lowest study) | $1,229 |
| One study, total annual cost per patient | $11,999 ($4,413 direct, $7,586 non-healthcare) |
| Non-healthcare share in that study | 63% |
| IBS-C treatment-failure cost vs success | $27,177 vs $19,998 a year |
Data source: American College of Gastroenterology, IBS infographic (2026); Cost-of-Illness of Irritable Bowel Syndrome: A Systematic Review, Journal of Gastroenterology and Hepatology (2026); International Foundation for Gastrointestinal Disorders via Persistence Market Research. The non-healthcare share and failure-cost gap come from individual studies in the review.
IBS costs the US health system billions, and estimates vary widely. The ACG puts direct medical costs at $1.5 billion to $10 billion a year, excluding prescription and over-the-counter drugs, while the International Foundation for Gastrointestinal Disorders cites more than $20 billion in total direct and indirect costs and more than 3.1 million physician visits. The range of $1.5 billion to $10 billion spans a factor of 6.7 (report calculation), a sign of differences in method and year.
Per-patient costs vary even more. A 2026 systematic review of 33 studies found annual direct healthcare costs per US patient from $1,661 to $31,113 for IBS-C. In one US study, non-healthcare costs such as lost work were 63% of total annual costs of $11,999. IBS-C patients who failed treatment incurred $27,177 a year against $19,998 for those who responded. These figures show that Irritable Bowel Syndrome Statistics in US 2026 on cost depend on severity as much as on prevalence.
IBS Treatment Landscape in the US 2026: AGA Guidelines and Approved Drugs
FDA-APPROVED AGENTS BY IBS SUBTYPE (COUNT LISTED)
IBS-C agents (AGA 2022) ████████████████████████████████████████ 5
IBS-D agents (named) ████████████████████████░░░░░░░░░░░░░░░░ 3
| Subtype | Drugs Named in the Sources | AGA 2022 Recommendation |
|---|---|---|
| IBS-C | Linaclotide, plecanatide, lubiprostone, tegaserod, tenapanor (5 FDA-approved) | Strong for linaclotide; conditional for plecanatide, tegaserod, lubiprostone and tenapanor |
| IBS-D | Rifaximin, eluxadoline, alosetron (alosetron for women with severe IBS-D) | AGA and ACG guidance updated for IBS-D in 2022 and 2021 |
| IBS-D share of treatment market, 2026 | About 50% | Market estimate |
| IBS-D share of patients in clinical studies | About 40% | Market estimate |
| Dietary and OTC options | Diet changes, over-the-counter medications | Listed by ACG in 2026 |
| Guideline update | AGA clinical practice guideline on IBS-C and IBS-D | 2022 |
Data source: U.S. Pharmacist, The Burden of Irritable Bowel Syndrome (AGA 2022 guideline summary); Persistence Market Research (2026 market estimate); American College of Gastroenterology IBS infographic (2026); AJMC. This table is informational and not medical advice.
The AGA updated its pharmacologic guidelines for IBS-C and IBS-D in 2022. For IBS-C, five agents are FDA-approved: linaclotide, plecanatide, lubiprostone, tegaserod and tenapanor. The AGA strongly recommends linaclotide and conditionally recommends the other four. For IBS-D the guidelines cover rifaximin and eluxadoline, and alosetron is approved for women with severe IBS-D.
Treatment is also built on diet and non-prescription measures. The ACG’s 2026 infographic lists diet, over-the-counter medications and prescription drugs, and it says there are treatment options even though IBS is a long-term condition. Market analysts estimate that IBS-D makes up about 50% of the 2026 treatment market, though IBS-D is only about 28%–40% of cases. These facts round out Irritable Bowel Syndrome Statistics in US 2026. People with symptoms should speak to a clinician.
Irritable Bowel Syndrome in US 2026 FAQ
What Percentage of Americans Have IBS in 2026?
Estimates range from 4.7% to 6.1% under Rome IV criteria and about 8.8% under Rome III. The commonly cited figure of about 12% comes from older surveys and broader criteria.
Why Do IBS Prevalence Numbers Differ in 2026?
Rome III counted milder or less frequent pain, while Rome IV requires abdominal pain at least once a week, which roughly halves prevalence. Surveys also differ in sample and method.
How Common Is IBS in Women Compared With Men in 2026?
In a US, Canada and UK sample, Rome IV prevalence was 6.1% in women and 3.2% in men, a ratio of about 1.9. Rome III prevalence was 12.2% and 5.8%.
What Are the Types of IBS in 2026?
IBS-M (mixed) at 33.9%, IBS-C (constipation) at 33.6%, IBS-D (diarrhea) at 28.1% and IBS-U (unclassified) at 4.4% in a US nationwide Rome IV survey.
What Is the Most Common Type of IBS in the US in 2026?
IBS-M and IBS-C were nearly tied in the nationwide survey (33.9% and 33.6%), while a three-country survey found IBS-D most common at 35.0%.
How Is IBS Diagnosed in 2026?
By symptoms, using the Rome IV criteria: abdominal pain at least one day a week for three months, linked to defecation or changes in stool frequency or form, with onset at least six months earlier. No blood test confirms it.
What Are the Symptoms of IBS in 2026?
Abdominal pain, bloating, distension and changes in bowel habits, with diarrhea, constipation or both. Some patients also report a feeling of incomplete evacuation or mucus in stool.
What Are Warning Signs That Need Testing in 2026?
Anemia, rectal bleeding, unintentional weight loss and a family history of colorectal cancer or inflammatory bowel disease are red flags that prompt further evaluation.
How Much Does IBS Cost the US in 2026?
The American College of Gastroenterology cites direct medical costs of $1.5 billion to $10 billion a year. Another source cites more than $20 billion in total direct and indirect costs.
How Many Doctor Visits Are for IBS in the US in 2026?
Over 3.1 million physician visits a year, according to the International Foundation for Gastrointestinal Disorders.
Does IBS Affect Younger Adults More in 2026?
In the 2023 US nationwide survey, younger adults and women had higher odds of meeting Rome IV criteria.
Can IBS Start After an Infection in 2026?
Yes. Post-infectious IBS follows gastroenteritis and accounts for from 7% to more than one-third of cases in pooled studies.
What Treatments Exist for IBS in 2026?
Diet changes, over-the-counter medications and prescription drugs. For IBS-C the AGA strongly recommends linaclotide, and for IBS-D rifaximin and eluxadoline are among approved options. Speak to a clinician before starting any treatment.
Disclaimer: The data research report we present here is based on information found from various sources. We are not liable for any financial loss, errors, or damages of any kind that may result from the use of the information herein. We acknowledge that though we try to report accurately, we cannot verify the absolute facts of everything that has been represented.
